Helios Inc. (ヘリオス株式会社, Heriosu Kabushiki-gaisha) is a Japanese biotechnology company headquartered in Tokyo, Japan, focused on developing innovative therapies for neurodegenerative diseases through a combination of small molecule drugs and regenerative medicine approaches. The company was founded in 2015 and has developed a pipeline targeting Alzheimer's disease, Parkinson's disease, and other central nervous system disorders.
Company Information
| Attribute | Details | |-----------|---------| | Stock Ticker | TSE 4595 | | Headquarters | Tokyo, Japan | | Founded | 2015 | | CEO | Yoshiro Miyazaki | | Website | https://www.helios.co.jp/ | | IPO | Tokyo Stock Exchange Growth Market (2019) |
History and Background
Helios Inc. was established in 2015 by a team of researchers from the University of Tokyo and Tokyo Institute of Technology, combining expertise in medicinal chemistry, neurobiology, and stem cell biology. The company's name reflects its mission to bring "light" (helios = sun in Greek) to patients suffering from neurodegenerative diseases.
The company went public on the Tokyo Stock Exchange Growth Market in 2019, using the proceeds to expand its drug discovery pipeline and clinical development programs.
Research Focus
Neurodegeneration Pipeline
Helios focuses on several key areas:
Alzheimer's Disease
Tau aggregation inhibitors: Small molecules targeting [tau protein](/proteins/tau) pathology
Amyloid-beta modulators: Compounds that modulate [amyloid-beta](/proteins/amyloid-beta) production and clearance
Neuroprotective agents: Compounds protecting [neurons](/cell-types/neurons) from various insults
HEL-101 is a [tau aggregation inhibitor](/mechanisms/tau-aggregation) that has completed Phase 1 clinical trials in Japan. The compound showed favorable safety and pharmacokinetics in healthy volunteers, and plans are underway for Phase 2 trials in [Alzheimer's disease](/diseases/alzheimers-disease) patients.
The mechanism involves binding to [tau protein](/proteins/tau) fibrils and preventing their propagation, potentially slowing disease progression rather than just treating symptoms.
Partnerships
Helios has established several pharmaceutical partnerships:
Collaboration with Daiichi Sankyo: Co-development of CNS drug candidates
Academic partnerships: University of Tokyo, Kyoto University, RIKEN
Contract research: Services for larger pharmaceutical companies
Financial Overview
Market cap: Approximately ¥3-5 billion
Cash position: Strong following Series C funding in 2022
R&D expenditure: Approximately ¥500 million annually